JBC Advanced Glycation Endproducts

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M205277200 on October 21, 2002

J. Biol. Chem., Vol. 277, Issue 52, 50386-50395, December 27, 2002
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/52/50386    most recent
M205277200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Somwar, R.
Right arrow Articles by Klip, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Somwar, R.
Right arrow Articles by Klip, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A Dominant-negative p38 MAPK Mutant and Novel Selective Inhibitors of p38 MAPK Reduce Insulin-stimulated Glucose Uptake in 3T3-L1 Adipocytes without Affecting GLUT4 Translocation*

Romel SomwarDagger §, Sandra Koterski||, Gary SweeneyDagger **, Richard Sciotti||, Stevan Djuric||, Cathy Berg||, James Trevillyan||, Philipp E. SchererDagger Dagger , Christina M. Rondinone||, and Amira KlipDagger §§§

From the Dagger  Programme in Cell Biology, Hospital for Sick Children, Toronto, Ontario M5G 1X8, the § Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada, || Diabetes Research, Pharmaceutical Products Division, Abbott Laboratories, and Dagger Dagger  Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461

Participation of p38 mitogen-activated protein kinase (p38) in insulin-induced glucose uptake was suggested using pyridinylimidazole p38 inhibitors (e.g. SB203580). However, the role of p38 in insulin action remains controversial. We further test p38 participation in glucose uptake using a dominant-negative p38 mutant and two novel pharmacological p38 inhibitors related to but different from SB203580. We present the structures and activities of the azaazulene pharmacophores A291077 and A304000. p38 kinase activity was inhibited in vitro by A291077 and A304000 (IC50 = 0.6 and 4.7 µM). At higher concentrations A291077 but not A304000 inhibited JNK2alpha (IC50 = 3.5 µM). Pretreatment of 3T3-L1 adipocytes and L6 myotubes expressing GLUT4myc (L6-GLUT4myc myotubes) with A291077, A304000, SB202190, or SB203580 reduced insulin-stimulated glucose uptake by 50-60%, whereas chemical analogues inert toward p38 were ineffective. Expression of an inducible, dominant-negative p38 mutant in 3T3-L1 adipocytes reduced insulin-stimulated glucose uptake. GLUT4 translocation to the cell surface, immunodetected on plasma membrane lawns of 3T3-L1 adipocytes or on intact L6-GLUT4myc myotubes, was not altered by chemical or molecular inhibition of p38. We propose that p38 contributes to enhancing GLUT4 activity, thereby increasing glucose uptake. In addition, the azaazulene class of inhibitors described will be useful to decipher cellular actions of p38 and JNK.

* This work was supported in part by Research Grant MT1202 from the Canadian Institutes for Health Research (to A. K.) and by Grant IR01-DK55758 from the National Institutes of Health (to P. E. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by a doctoral award from the Canadian Institutes for Health Research.

** Supported by a joint postdoctoral fellowship from the Banting and Best Diabetes Centre at the University of Toronto and Novo Nordisk Canada.

§§ To whom correspondence should be addressed: Programme in Cell Biology, Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, Canada. Tel.: 416-813-6392; Fax: 416-813-5028; E-mail: amira@sickkids.ca.

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
V. Kaddai, T. Gonzalez, M. Bolla, Y. Le Marchand-Brustel, and M. Cormont
The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3-L1 adipocytes
Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E162 - E169.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Emanuelli, D. Eberle, R. Suzuki, and C. R. Kahn
Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance
PNAS, March 4, 2008; 105(9): 3545 - 3550.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. B. Dokken, V. Saengsirisuwan, J. S. Kim, M. K. Teachey, and E. J. Henriksen
Oxidative stress-induced insulin resistance in rat skeletal muscle: role of glycogen synthase kinase-3
Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E615 - E621.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
H. F. Kramer and L. J. Goodyear
Exercise, MAPK, and NF-{kappa}B signaling in skeletal muscle
J Appl Physiol, July 1, 2007; 103(1): 388 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Choudhary and H.-C. R. Wang
Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells
Mol. Cancer Ther., March 1, 2007; 6(3): 1099 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Xiong, Q. F. Collins, J. An, E. Lupo Jr., H.-Y. Liu, D. Liu, J. Robidoux, Z. Liu, and W. Cao
p38 Mitogen-activated Protein Kinase Plays an Inhibitory Role in Hepatic Lipogenesis
J. Biol. Chem., February 16, 2007; 282(7): 4975 - 4982.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Konstantopoulos, S. Marcuccio, S. Kyi, V. Stoichevska, L. A. Castelli, C. W. Ward, and S. L. Macaulay
A Purine Analog Kinase Inhibitor, Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor 59, Reveals a Role for Calcium/Calmodulin-Dependent Protein Kinase II in Insulin-Stimulated Glucose Transport
Endocrinology, January 1, 2007; 148(1): 374 - 385.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. J. F. P. Luiken, I. Momken, D. D. J. Habets, M. El Hasnaoui, W. A. Coumans, D. P. Y Koonen, J. F. C. Glatz, and A. Bonen
Arsenite Modulates Cardiac Substrate Preference by Translocation of GLUT4, But Not CD36, Independent of Mitogen-Activated Protein Kinase Signaling
Endocrinology, November 1, 2006; 147(11): 5205 - 5216.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. Mari, P. Monzo, V. Kaddai, F. Keslair, T. Gonzalez, Y. Le Marchand-Brustel, and M. Cormont
The Rab4 effector Rabip4 plays a role in the endocytotic trafficking of Glut 4 in 3T3-L1 adipocytes
J. Cell Sci., April 1, 2006; 119(7): 1297 - 1306.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Turban, V. A. Beardmore, J. M. Carr, K. Sakamoto, E. Hajduch, J. S. C. Arthur, and H. S. Hundal
Insulin-Stimulated Glucose Uptake Does Not Require p38 Mitogen-Activated Protein Kinase in Adipose Tissue or Skeletal Muscle
Diabetes, November 1, 2005; 54(11): 3161 - 3168.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. Li, E. J. Miller, J. Ninomiya-Tsuji, R. R. Russell III, and L. H. Young
AMP-Activated Protein Kinase Activates p38 Mitogen-Activated Protein Kinase by Increasing Recruitment of p38 MAPK to TAB1 in the Ischemic Heart
Circ. Res., October 28, 2005; 97(9): 872 - 879.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Yamaguchi, H. Katahira, S. Ozawa, Y. Nakamichi, T. Tanaka, T. Shimoyama, K. Takahashi, K. Yoshimoto, M. O. Imaizumi, S. Nagamatsu, et al.
Activators of AMP-activated protein kinase enhance GLUT4 translocation and its glucose transport activity in 3T3-L1 adipocytes
Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E643 - E649.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. N. Antonescu, C. Huang, W. Niu, Z. Liu, P. A. Eyers, K. A. Heidenreich, P. J. Bilan, and A. Klip
Reduction of Insulin-Stimulated Glucose Uptake in L6 Myotubes by the Protein Kinase Inhibitor SB203580 Is Independent of p38MAPK Activity
Endocrinology, September 1, 2005; 146(9): 3773 - 3781.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Pelletier, E. Joly, M. Prentki, and L. Coderre
Adenosine 5'-Monophosphate-Activated Protein Kinase and p38 Mitogen-Activated Protein Kinase Participate in the Stimulation of Glucose Uptake by Dinitrophenol in Adult Cardiomyocytes
Endocrinology, May 1, 2005; 146(5): 2285 - 2294.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. Ribe, J. Yang, S. Patel, F. Koumanov, S. W. Cushman, and G. D. Holman
Endofacial Competitive Inhibition of Glucose Transporter-4 Intrinsic Activity by the Mitogen-Activated Protein Kinase Inhibitor SB203580
Endocrinology, April 1, 2005; 146(4): 1713 - 1717.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Bazuine, F. Carlotti, M. J. W. E. Rabelink, J. Vellinga, R. C. Hoeben, and J. A. Maassen
The p38 Mitogen-Activated Protein Kinase Inhibitor SB203580 Reduces Glucose Turnover by the Glucose Transporter-4 of 3T3-L1 Adipocytes in the Insulin-Stimulated State
Endocrinology, April 1, 2005; 146(4): 1818 - 1824.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
P. C. Geiger, D. C. Wright, D.-H. Han, and J. O. Holloszy
Activation of p38 MAP kinase enhances sensitivity of muscle glucose transport to insulin
Am J Physiol Endocrinol Metab, April 1, 2005; 288(4): E782 - E788.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. S. Hutchinson and T. Bengtsson
{alpha}1A-Adrenoceptors Activate Glucose Uptake in L6 Muscle Cells through a Phospholipase C-, Phosphatidylinositol-3 Kinase-, and Atypical Protein Kinase C-Dependent Pathway
Endocrinology, February 1, 2005; 146(2): 901 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. W. Harmon, D. S. Paul, and Y. M. Patel
MEK inhibitors impair insulin-stimulated glucose uptake in 3T3-L1 adipocytes
Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E758 - E766.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
R. B. Ceddia and G. Sweeney
Creatine supplementation increases glucose oxidation and AMPK phosphorylation and reduces lactate production in L6 rat skeletal muscle cells
J. Physiol., March 1, 2004; 555(2): 409 - 421.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. C. Ho, O. Alcazar, N. Fujii, M. F. Hirshman, and L. J. Goodyear
p38{gamma} MAPK regulation of glucose transporter expression and glucose uptake in L6 myotubes and mouse skeletal muscle
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R342 - R349.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Perrini, A. Natalicchio, L. Laviola, G. Belsanti, C. Montrone, A. Cignarelli, V. Minielli, M. Grano, G. De Pergola, R. Giorgino, et al.
Dehydroepiandrosterone Stimulates Glucose Uptake in Human and Murine Adipocytes by Inducing GLUT1 and GLUT4 Translocation to the Plasma Membrane
Diabetes, January 1, 2004; 53(1): 41 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Tardif, N. Julien, J.-L. Chiasson, and L. Coderre
Stimulation of glucose uptake by chronic vanadate pretreatment in cardiomyocytes requires PI 3-kinase and p38 MAPK activation
Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1055 - E1064.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Niu, C. Huang, Z. Nawaz, M. Levy, R. Somwar, D. Li, P. J. Bilan, and A. Klip
Maturation of the Regulation of GLUT4 Activity by p38 MAPK during L6 Cell Myogenesis
J. Biol. Chem., May 9, 2003; 278(20): 17953 - 17962.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. J. Carlson, S. Koterski, R. J. Sciotti, G. B. Poccard, and C. M. Rondinone
Enhanced Basal Activation of Mitogen-Activated Protein Kinases in Adipocytes From Type 2 Diabetes: Potential Role of p38 in the Downregulation of GLUT4 Expression
Diabetes, March 1, 2003; 52(3): 634 - 641.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
K. V. Kandror
A Long Search for Glut4 Activation
Sci. Signal., February 11, 2003; 2003(169): pe5 - pe5.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.